LRRK2 = Leucine-Rich Repeat kinase 2, PLK-2i = PLK-2 inhibitor, GSK-3i XV = pan GSK-3 inhibitor XV, FCS = fetal calf serum, WB = western blotting, SD = standard deviation, pS9 = phosphorylation of serine 9 of GSK-3, pS935 = phosphorylation of serine 935 of LRRK2, pS396 = phosphorylation of serine 396 of Tau, MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, SNPs = single nucleotide polymorphisms Background The aetiology of Parkinson's disease (PD) is to a great extend still unknown, but increased αsynuclein levels is enough to cause the development of autosomal dominant familial PD in individuals with duplications or triplications of the gene encoding α-synuclein, SNCA. These abnormal α-synuclein levels induce PD in a dose-dependent manner, since patients with SNCA triplications suffer from a more severe phenotype with earlier onset than those having duplications (Chartier-Harlin et al., 2004; Farrer et al., 2004; Lesage and Brice, 2009; Singleton et al., 2003) .
The importance of α-synuclein levels in the development of PD is further supported by genomewide association studies (GWAS) demonstrating that variations in SNCA is a risk factor for sporadic PD (Edwards et al., 2010) , some of which has been shown to increase α-synuclein expression (Farrer et al., 2001; Fuchs et al., 2008) . use of this finding as a therapeutic strategy. Instead, unravelling of the underlying pathway might reveal other suitable targets, which could be modulated to decrease α-synuclein.
The regulation of α-synuclein by PLK-2 is kinase activity-dependent (Kofoed et al., 2017; Oueslati et al., 2013) , and we therefore hypothesize that PLK-2 phosphorylates Glycogen Synthase kinase 3 β (GSK-3β) and hereby modulates α-synuclein mRNA expression. GSK-3β is known to regulate several transcription factors and it is inhibited by PLK-2 through phosphorylation at serine 9 (Li et al., 2014; Lim et al., 2015) . Additionally, α-synuclein is increased in transgenic mice overexpressing a constitutive active GSK-3β (Credle et al., 2015) . It was therefore investigated in this study whether GSK-3β is a possible downstream mediator of the PLK-2-dependent regulation of α-synuclein using two different GSK-3β inhibitors: GSK-3i XV (Atilla-Gokcumen et al., 2006) and Tideglusib (Domínguez et al., 2012) . Our results demonstrate that the PLK-2-mediated regulation of α-synuclein mRNA is indeed GSK-3β-dependent and inhibition of PLK-2 in vivo increases phosphorylation of the well-known GSK-3 substrate Tau and increases α-synuclein levels. Inhibition of GSK-3β in HEK293T cells using GSK-3i XV, Tideglusib or shRNA-mediated knockdown decreases α-synuclein and overexpression of a known activator of GSK-3, Leucine-Rich Repeat kinase 2 (LRRK2) (Kawakami et al., 2014; Lin et al., 2010) , increases α-synuclein.
Finally, we also demonstrate in primary neurons that regulation of -synuclein by PLK-2 is GSK-3 dependent, and that increased GSK-3 activity increases both Tau phosphorylation and endogenous -synuclein levels. Our findings describe for the first time in detail a GSK-3mediated regulation of -synuclein protein and mRNA levels.
(Sigma, A5441), anti-Tau was made in-house and raised against full-length recombinant human tau (2N4R) 1:1000, anti-pS935-LRRK2 1:1000 (Abcam, ab133450), anti-pS396-Tau 1:2000 (ThermoFischer, 44752G), anti-LRRK2 1:5 (NeuroMab, TC Supernatant N241A/34), anti-GSK-3 1:1000 (Cell Signaling, 9315), anti-pS9 GSK-3 1:1000 (Cell Signaling, 9322), anti-mouse-synuclein 1:1000 (Cell Signaling, 4179), and anti-III-tubulin (80120, Biolegend). Secondary antibodies were purchased from Dako. PageRuler Prestained Protein Ladder 10-180 kDa (Thermo Fischer, 26616) was used to calculate the molecular weight of protein bands (Thermo Fischer, 26619, was used for LRRK2).
Reverse transcription and quantitative polymerase chain reaction (RT-qPCR)
RNA was extracted using High Pure RNA Isolation Kit (Roche, 11, 828, 665, 001) and analysed by RT-qPCR as previously described (Kofoed et al., 2017) . The following probes were used for qPCR: α-synuclein human (SNCA, Hs01103383_m1), 18s RNA human (RNA18s, Hs00609296_g1), GSK-3β human (Hs01047719_m1), LRRK2 human (Hs01115057_m1).
Statistics
Statistical evaluation of two groups was performed using Student's t-test and for multiple comparisons using one-way ANOVA with Tukey's post hoc test. Presented data show mean  standard deviation (SD) and p-values * p<0.05, **p<0.01, ***p<0.001. The data obtained from primary neuronal cultures included normalization to the corresponding DMSO for each pup, leading to a non-normal distribution of the DMSO group. For statistical evaluation non-parametric Krustal-Wallis was performed followed by post hoc Mann-Whitney. Data is presented as mean  SD and * indicates rejection of the null hypothesis and p<0.05. All experiments were performed a minimum of n=3.
Results

Inhibition or knockdown of GSK-3β decreases α-synuclein
HEK293T cell model (Kofoed et al., 2017) . HEK293T cells were transfected with α-synuclein and 4 h later treated for 16 h with the pan-GSK-3 inhibitor XV (GSK-3i XV) (Atilla-Gokcumen et al., 2006) . In accordance with our hypothesis, GSK-3i XV treatment decreased α-synuclein compared to DMSO ( Figure 1A ). GSK-3i XV is an ATP-competitive inhibitor, which can lead to off-target effects because of the similarity between ATP-binding sites in different kinases, and GSK-3i XV is known to inhibit both GSK-3β and GSK-3α (Atilla-Gokcumen et al., 2006) . To ensure that the effects seen on α-synuclein by GSK-3i XV treatment are due to inhibition of GSK-3β, the finding was confirmed using shRNA-mediated knockdown of GSK-3β by expressing α-synuclein in HEK293T cells together with shGSK-3 or shCtrl ( Figure 1B ). Because both α-synuclein and GSK-3β have long halflives (Domínguez et al., 2012; Kofoed et al., 2017) , the cells were left to express shRNA for 4 days prior to WB and RT-qPCR analysis. The results show that expression of shGSK-3β decreases α-synuclein compared to cells expressing shCtrl ( Figure 1B ). This supports that the decrease in α-synuclein upon GSK-3i XV treatment happens through inhibition of GSK-3β. The knockdown of GSK-3β mRNA was measured to be only 25% ( Figure 1C ), however the transfection efficiency was 60-70% and the knockdown in the transfected cells are therefore likely to be higher.
We saw a more pronounced reduction of -synuclein levels when inhibiting cells with GSK-3i XV treatment ( Figure 1A ) compared to shGSK-3 ( Figure 1B ), suggesting a more complete inhibition of GSK-3 when using the small molecule compound compared to shRNA.
PLK-2 regulates α-synuclein by modulating GSK-3β activity
Since both PLK-2 and GSK-3β regulates α-synuclein it was investigated if they are a part of the same mechanism by testing whether GSK-3β inhibition influences the previously shown increase in α-synuclein mRNA upon PLK-2 inhibition (Kofoed et al., 2017) . α-Synucleintransfected HEK293T cells were co-treated for 4 h with a PLK-2 specific inhibitor (PLK-2i) (Kofoed et al., 2017) alone or together with GSK-3i XV followed by measurement of changes in α-synuclein mRNA. As previously seen PLK-2i increased α-synuclein mRNA (Kofoed et al., 2017) ; however, this was abolished by simultaneous treatment with GSK-3i XV ( Figure 1D ). This suggests that PLK-2 inhibition increases α-synuclein mRNA in a GSK-3β-dependent manner, supporting the hypothesis of GSK-3β being the downstream target of PLK-2 kinase activity modulating αsynuclein mRNA expression. PLK-2 has previously been shown to regulate GSK-3 through phosphorylation of serine 9 (Li et al., 2014; Lim et al., 2015) . To investigate if the PLK-2-mediated regulation of -synuclein depends on phosphorylation of S9 on GSK-3, HEK293T cells were J o u r n a l P r e -p r o o f Journal Pre-proof transfected with -synuclein and PLK-2 or empty vector (Mock) and analyzed for levels of synuclein and GSK-3. PLK-2 overexpression decrease -synuclein as previously described (Kofoed et al., 2017) , however, it did not increase pS9 GSK-3 ( Figure 1E ). This suggests that PLK-2 either regulates GSK-3 directly by phosphorylating other sites or through phosphorylation of other proteins.
We have previously shown that chronic PLK-2i treatment for 10 days significantly increases αsynuclein protein levels in C57BL/6J mice (Kofoed et al., 2017) which according to our hypothesis happens through a GSK-3 activation. Phosphorylation of the microtubule-associated protein Tau (Tau) at S396 (pS396) is a well-established target of GSK-3β kinase activity (Bian et al., 2016 Credle et al., 2015 Ga ssowska et al., 2014 , and the level of pS396 Tau was therefore measured in the same PLK-2i-treated mice previously described in (Kofoed et al., 2017) as an indicator of GSK-3β activity. pS396 Tau levels were indeed increased by PLK-2 inhibition ( Figure 1F ) indicating that this treatment both increases α-synuclein protein levels as previously shown in these mice (Kofoed et al., 2017) and possibly also GSK-3β activity. From this experiment alone, however, it cannot be ruled out that the increase in pS396 Tau is caused by activation of another kinase. The changes in pS396 Tau were not caused by changes in total Tau levels, since these remained the same between the PLK-2i-and vehicle-treated group.
Overexpression of LRRK2 increases α-synuclein
The results presented in Figure 1 support that PLK-2 regulates α-synuclein via modulation of GSK-3β activity, and direct inhibition of GSK-3β also decreased α-synuclein levels in HEK293T cells.
To further test our hypothesis we investigated if activation of GSK-3β by other mechanisms than PLK-2 inhibition could also increase α-synuclein. To upregulate the activity of endogenous GSK-3, without the use of toxins previously shown to increase GSK-3 activity (Duka et al., 2009; Yuan et al., 2015) , we searched the literature for activators of GSK-3. The PD-associated kinase, Leucine-rich repeat kinase 2 (LRRK2), has been shown to increase GSK-3β activity through direct binding (Kawakami et al., 2014; Lin et al., 2010) , hereby upregulating GSK-3 activity in a different manner than PLK-2. Additionally, PD-related mutations in LRRK2 have been associated with increased phosphorylation of Tau and GSK-3 activity (Li et al., 2009; Melrose et al., 2010; Ohta et al., 2015) , though this is still debated (Ramonet et al., 2011; Weng et al., 2016) . It was therefore tested whether overexpression of LRRK2 increases α-synuclein. HEK293T cells transfected with α-synuclein and LRRK2, or Mock, demonstrated that overexpression of LRRK2 J o u r n a l P r e -p r o o f indeed increases α-synuclein compared to Mock ( Figure 2A+B ), as would be expected from an activation of GSK-3β. Overexpression of PLK-2 on the other hand decreases α-synuclein as seen before (Kofoed et al., 2017; Oueslati et al., 2013 ) ( Figure 2A+B ), and simultaneous expression of PLK-2 and LRRK2 completely abolished the increased α-synuclein induced by LRRK2 ( Figure   2A+B ), suggesting that the effects of PLK-2 abolishes that of LRRK2.
To investigate whether the LRRK2-induced increase in α-synuclein depends on GSK-3β activity, HEK293T cells were transfected with LRRK2 and treated with GSK-3i XV for 16 h. Inhibition of GSK-3β markedly reduced α-synuclein in the LRRK2-expressing cells to a level not significantly different from the Mock-transfected cells ( Figure 2A+B ). This supports that the increase in synuclein by LRRK2 overexpression is GSK-3 dependent.
GSK-3β and LRRK2 also modulates α-synuclein mRNA
PLK-2 regulates α-synuclein by modulating its mRNA expression (Kofoed et al., 2017) , and it was therefore measured if LRRK2 and GSK-3i XV also influence α-synuclein mRNA levels. The protein level is decreased after a 16 h treatment initiated 4 h after transfection ( Figure 1A ), and the mRNA was therefore measured in a similar setup, because Figure 1D shows that 4 h GSK-3i XV treatment initiated 24 h after transfection with -synuclein does not decrease α-synuclein mRNA.
Controlled inhibition of -synuclein mRNA expression in the HEK293T cell model is highly dependent on the time point where the treatment is initiated. Treatments starting 4 h after transfection will impact more on the ability of the treatment to keep the mRNA expression low, whereas treatments beginning 24 h post-transfection, are more dependent on the half-life of synuclein mRNA since cells will have expressed large amounts of the transgenic mRNA at this point.
α-Synucleintransfected HEK293T cells were treated with PLK-2i or GSK-3i XV for 16 h starting 4 h after -synuclein transfection. PLK-2i increased α-synuclein mRNA, corroborating our previous results shown in Figure 1D , and the 16 h treatment with GSK-3i XV induced a decrease ( Figure   2C ). This again supports that GSK-3β could regulate α-synuclein through the same mechanism as PLK-2 since they both change α-synuclein mRNA levels and GSK-3i XV blocks the positive effect of PLK-2i. LRRK2 overexpression in the same cells increased α-synuclein mRNA; however, not to the same extent as the protein levels ( Figure 2C ). The increase in α-synuclein protein levels by LRRK2 might therefore be influenced both by increased mRNA and by another mechanism such as regulation of degradative pathways, which LRRK2 is also known to modulate (Alegre-Abarrategui J o u r n a l P r e -p r o o f Lichtenberg et al., 2011; Orenstein et al., 2013; Ramonet et al., 2011; Y. Tong et al., 2010) . Inhibition of PLK-2 in cells overexpressing LRRK2 induced a further increase in αsynuclein mRNA compared to LRRK2-transfected cells treated with DMSO ( Figure 2C ) further supporting that inhibition of PLK-2 impacts the effect of LRRK2 on -synuclein expression ( Figure   2A+B ), and inhibition of PLK-2 therefore still has an additional effect in LRRK2 overexpressing cells. Similar to the results on α-synuclein protein levels, GSK-3i XV was able to inhibit the increase in α-synuclein mRNA by LRRK2 to a level not significantly different from GSK-3i XVtreated Mock-transfected cells ( Figure 2C ). These observations indicate that the α-synuclein increase mediated by LRRK2 is GSK-3β-dependent.
The highly similar LRRK2 paralogue LRRK1 (Taylor et al., 2007) was also tested for its effect on α-synuclein levels. Overexpression of LRRK1 together with α-synuclein in HEK293T cells did not, as LRRK2, increase α-synuclein compared to Mock but rather decreased it ( Figure 1D ). This suggests that the GSK-3β-dependent increase in α-synuclein is specific for LRRK2.
LRRK2-mediated regulation of α-synuclein is kinase and GTPase activity-independent
The regulation of GSK-3β by LRRK2 has been shown to be independent of the kinase activity of LRRK2 and both wild-type (wt) LRRK2, and two mutants, G2019S and D1994A, increasing and abolishing the kinase activity are all able to increase GSK-3β activity (Kawakami et al., 2014; Lin et al., 2010) . The increase in α-synuclein by LRRK2 overexpression should therefore also be kinase activity-independent if mediated by GSK-3β activation. The three LRRK2 variants (wt, G2019S, D1994A) were overexpressed in HEK293T cells together with α-synuclein, and they all induced an increase in α-synuclein compared to Mock ( Figure 3A) . This finding was supported by the inability of two LRRK2 kinase inhibitors, PFE-360 and Mli-2, to affect the increase in α-synuclein upon LRRK2 wt expression ( Figure 3B ), even though both compounds decreased LRRK2 kinase activity as measured by decreased pS935 LRRK2 levels (Sheng et al., 2012) (Figure 3B ). This suggests that the regulation of α-synuclein levels and GSK-3β activity by LRRK2 are both independent of its kinase activity, and the results are compatible with the two mechanisms being the same.
It was additionally investigated whether the GTPase-dead LRRK2 mutant T1348N, incapable of binding GTP, also increases α-synuclein upon overexpression in HEK293T cells. The T1348N LRRK2 mutant is unstable compared to LRRK2 wt when expressed in HEK293T cells (Biosa et al., 2013) . We confirmed that LRRK2 T1348N was expressed in lower levels than LRRK2 wt, but it still resulted in a significant increase in LRRK2 levels compared to Mock ( Figure 4A ). LRRK2 J o u r n a l P r e -p r o o f T1348N increased α-synuclein levels to the same extend as LRRK2 wt ( Figure 4B ), again advocating that the underlying mechanism is enzyme activity-independent and likely happens through a direct binding and allosteric activation of GSK-3β.
The GSK-3β inhibitor Tideglusib decreases both α-synuclein protein and mRNA levels
The GSK-3β inhibitor Tideglusib (Domínguez et al., 2012) has been proven safe in mice and humans (Bolós et al., 2010; Del Ser et al., 2013) and has been in clinical trials for Alzheimer's disease and progressive supranuclear palsy (Lovestone et al., 2015; Tolosa et al., 2014) .
Additionally, Tideglusib is a specific non-ATP competitive inhibitor and does, opposed to GSK-3i XV, only inhibit GSK-3β and not GSK-3α (Domínguez et al., 2012) . We investigated whether Tideglusib also decreases GSK-3β activity and α-synuclein levels in our cell model, by treating HEK293T cells transfected with α-synuclein and Tau with increasing doses of Tideglusib. This induced a dose-dependent decrease in α-synuclein and pS396 Tau levels, indicating decreased GSK-3β activity, as anticipated ( Figure 5A+B) . Changes in α-synuclein mRNA was, additionally, measured after 16 h Tideglusib treatment, and this also showed a significant decrease ( Figure 5C ).
The finding that two very different inhibitors of GSK-3β, GSK-3i XV and Tideglusib, as well as shGSK-3β expression all decrease α-synuclein levels supports that this is indeed because GSK-3β inhibits -synuclein production.
PLK-2 regulates  -synuclein in a GSK-3 -dependent manner in primary neurons
To investigate if -synuclein regulation by PLK-2 is also GSK-3-dependent in a more physiological setting, mouse primary cortical neurons (DIV 13) were treated for 20 h with PLK-2i together with Tideglusib, or DMSO. PLK-2i significantly increased -synuclein protein levels as previously seen in primary hippocampal neurons (Kofoed et al., 2017) and this was inhibited by treatment with Tideglusib ( Figure 5D ). This supports that the regulation of endogenous -synuclein by endogenous PLK-2 happens through regulation of GSK-3 activity. We did not see a decrease in -synuclein protein levels in primary cortical neurons after 20 h treatment with Tideglusib ( Figure   5D ). Rotenone and increased exogenous -synuclein levels have previously been demonstrated to increase GSK-3 activity (Duka et al., 2009 Ga ssowska et al., 2014 uan et al., 2010 . To investigate the effect of increased GSK-3 activity on endogenous -synuclein we therefore treated mouse primary cortical neurons with rotenone (DIV 13) or recombinant monomeric and fibrillary human -synuclein (DIV 7) and lysed the cells at DIV 14 ( Figure 6 ). Rotenone did not lead to any significant changes in these experiments. However, treatment with both monomeric and fibrillary human -synuclein increased GSK-3 levels significantly and did not change pS9 GSK-3, suggesting an overall increase in GSK-3 activity. This was supported by an increase in pS396 Tau, a known target of GSK-3. The total level of Tau was also increased by both monomeric and fibrillary -synuclein. To investigate the effect on endogenous -synuclein, a mouse -synuclein specific antibody was used in order to distinguish endogenous mouse -synuclein from exogenous human -synuclein. To ensure no cross reactivity of the mouse -synuclein specific antibody with the human recombinant -synuclein, the samples were run again together with 20 ng recombinant human -synuclein ( Supplementary Figure 2) . This revealed that endogenous mouse -synuclein was increased upon treatment with exogenous human -synuclein, which supports that increased GSK-3 activity increases endogenous -synuclein levels. Of note, fibrillary human -synuclein increased endogenous mouse -synuclein significantly more than monomeric human -synuclein.
This was in contrast to the level of GSK-3 and pS396 Tau which increased to the same extent compared to control irrespective of -synuclein species. This suggests that the fibrillary form of synuclein can facilitate additional effects on -synuclein expression that may be due to templated aggregation of endogenous -synuclein, which may even be in an GSK-3-independent manner. However, deciphering this mechanism is outside the scope of this report.
Discussion
GSK-3 as a target to decrease  -synuclein
We have previously shown that PLK-2 regulates -synuclein protein levels by modulating synuclein mRNA expression and does not affect -synuclein degradation or translation (Kofoed et al., 2017) . The goal of this study was to characterize the role of GSK-3 in the down-stream signaling pathway responsible for the PLK-2-mediated regulation of -synuclein. We found that PLK-2 regulates -synuclein mRNA levels via GSK-3 (Figure 7) , and in HEK293T cells we saw a J o u r n a l P r e -p r o o f decrease in -synuclein when inhibiting GSK-3 for 16 h. Importantly, in this setup, GSK-3 inhibition was initiated 4 h after transfection, and the effect on -synuclein mRNA was therefore started prior to the presence of a high level of -synuclein in the cells. In primary neurons, Tideglusib inhibited the PLK-2i-induced increase in -synuclein protein levels, but 20 h Tideglusib treatment did not decrease -synuclein protein levels. In primary neurons, the inhibition of GSK-3 is initiated after 13 days in vitro were -synuclein protein is already present in the neurons (Li et al., 2004) as opposed to the setup in HEK293T cells. The inability of 20 h GSK-3 inhibition to decrease -synuclein in primary neurons might therefore be due to the long half-life of -synuclein protein in primary neurons, found to be 50 h in primary cortical neurons (Li et al., 2004) .
The regulation of endogenous -synuclein by GSK-3 was investigated by activating GSK-3 using recombinant -synuclein. This significantly increased GSK-3 levels as well as pS396 Tau and endogenous mouse -synuclein, supporting that increased GSK-3 activity increases endogenous -synuclein levels. Additionally, the data suggests that a vicious cycle might exist between GSK-3 and -synuclein, where increased GSK-3 activity can increase -synuclein levels and vice versa.
Others have shown that treatment with Tideglusib in a transgenic mouse model of amyloid- and Tau pathology affects phosphorylation of Tau at GSK-3 targeted sites but only in 15 month old animals, suffering from behavioral deficits, and not in pre-symptomatic 12-months old mice (Serenó et al., 2009 ). This suggests that GSK-3 activity is increased during pathological conditions. It is possible that inhibition of GSK-3 needs to be tested in a pathological setting with increased GSK-3 activity, such as mice overexpressing -synuclein (Duka et al., 2009) , to see an effect on -synuclein levels. This criteria might be present in the -synuclein transfected HEK293T cell model used here, because high levels of exogenous -synuclein has been shown to increase GSK-3 activity in cells (Yuan et al., 2010) .
The interaction between GSK-3 and -synuclein is generally not well described. Many animal studies have focused on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone induced models, which are lacking the progressive neurodegeneration (Heikkila et al., 1985) . The models do, however, suggest a relationship between GSK-3 and -synuclein and show a dependency of MPTP-induced GSK-3 activation and -synuclein expression, as well as a lack of -synuclein increase by either MPTP or rotenone during GSK-3 inhibition (Duka et al., 2009;  J o u r n a l P r e -p r o o f Journal Pre-proof Kozikowski et al., 2006; Yuan et al., 2015) . Additionally, overexpression of constitutive active GSK-3β in mice induces PD like motor dysfunctions and increases α-synuclein (Credle et al., 2015) . Finally, overexpression of α-synuclein in cells and mice also increases GSK-3β activity (Duka et al., 2009 Ga ssowska et al., 2014 Yuan et al., 2010) , supporting our data suggesting that a vicious cycle might exist between increased GSK-3β activity and α-synuclein pathology. Even though -synuclein protein levels are not increased in PD (J. , it remains to be investigated if specific cells or brain areas show a correlation between GSK-3 activity and synuclein levels. Interestingly, increased phosphorylation of the activating pY216 site in GSK-3 has been observed in Lewy bodies (Credle et al., 2015) .
A possible decrease in α-synuclein is not the only finding suggesting GSK-3β as a target for PD treatment. GSK-3β activity is increased in PD patients (Duka et al., 2009; Nagao and Hayashi, 2009; Wills et al., 2010) , and one SNP in GSK-3β has been found to increase both GSK-3β promoter activity and the risk of PD in Caucasians (Kwok et al., 2005) , though this finding was not replicated in a Chinese population (Yu et al., 2014) . Additionally, the upstream inhibitor of GSK-3β, Akt1, has a decreased activity in PD (Timmons et al., 2009) . This suggests that GSK-3β could also be directly involved in PD associated pathology and development.
LRRK2 increases α-synuclein in a GSK-3β-dependent manner
As a possible downstream target of PLK-2, direct activation of GSK-3β by another mechanism than PLK-2i treatment should also increase α-synuclein levels. LRRK2 is a PD-related kinase, which has been shown to activate GSK-3β upon direct binding (Kawakami et al., 2014; Lin et al., 2010) , and LRKK2 overexpression indeed increased α-synuclein protein and mRNA levels in our HEK293T cell model in a GSK-3-dependent manner. LRRK2 activates GSK-3β through a direct binding and the mechanism is independent of LRRK2 kinase activity (Kawakami et al., 2014; Lin et al., 2010) , which was also seen in our model. Overexpression of PLK-2 abolished the effect of LRRK2 overexpression and PLK-2 inhibition further increased -synuclein in LRRK2 overexpressing cells.
Based on these findings, we hypothesize that LRRK2 cannot activate the pool of GSK -3 which is inhibited by PLK-2, and future studies are needed to further unravel this relationship. LRRK2 is closely related to PD because it, like the α-synuclein gene SNCA, is responsible for autosomal dominant familial PD and LRRK2 and SNCA are both genetic risk factors for sporadic PD based in GWAS (Shu et al., 2019) . Interestingly, LRRK2 and α-synuclein increase simultaneously in J o u r n a l P r e -p r o o f Journal Pre-proof neurons in the substantia nigra prior to Lewy Body formation (Guerreiro et al., 2013) . This could be explained by an activation of GSK-3β by LRRK2, which would then cause an increase in αsynuclein expression according to our findings (Figure 7) .
Treating Parkinson's disease by decreasing  -synuclein
Several findings suggest a link between -synuclein concentrations and the initiation and progression of -synuclein pathology and PD. The most striking link is the development of familial PD in individuals carrying multiplications of non-mutated SNCA, which demonstrates an synuclein dose-dependent severity and progression of the disease . However, smaller increases in -synuclein also affects the risk of developing PD, and certain single nucleotide polymorphisms (SNPs) in SNCA have been discovered to increase both -synuclein expression and the risk of PD (Fuchs et al., 2008) . A recent study also demonstrated that adrenoreceptor agonists decreases -synuclein protein levels by approximately 20-30%, and consumption of these compounds is enough to reduce the risk of developing PD (Mittal et al., 2017) . Interestingly, it has been demonstrated that siRNA-mediated knock down of -synuclein in transgenic mice after the development of -synuclein pathology decreased not only the soluble synuclein but also the insoluble forms after only 7 days of treatment (Cooper et al., 2014) . This suggests that even though it is not possible to reverse the cell death by decreasing -synuclein, it might be possible to decrease some of the already ongoing pathology, and not only the further spreading.
Conclusion
Although, it has been demonstrated that overexpression of GSK-3 wt in cells and a constitutive active GSK-3 mutant in mice increases -synuclein protein levels (Credle et al., 2015; Yuan et al., 2015) , to the best of our knowledge, this is the first in-depth study on the role of endogenous GSK-3 in the PLK-2-mediated regulation of -synuclein mRNA and protein levels. Future investigations should determine if GSK-3 inhibition decreases -synuclein in vivo and modulates progression of -synuclein pathology in PD models. Interestingly, inhibition of GSK-3 was recently hypothesized to play a role in the decreased risk of PD in smokers, due to the high levels of lithium in tobacco (Jr, 2019) . GSK-3 inhibition as a treatment for PD would be an ideal target J o u r n a l P r e -p r o o f Journal Pre-proof because it can be inhibited by small molecule compounds, some of which have already been approved for clinical trials (Martinez et al., 2011) .
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can activate GSK-3 through direct binding (Kawakami et al., 2014; Lin et al., 2010) 
